Federal Circuit: Indefiniteness Is Not Judged by the 'Claim Language, Standing Alone'

Feb 22, 2022

Reading Time : 2 min

In Nature Simulations Systems, Inc. v. Autodesk, Inc., the patent owner asserted two patents related to methods for building 3-D models. The district court held both patents invalid, finding that multiple claim terms raised “unanswered questions” that render the claims indefinite. The district court further rejected the patent owner’s argument that the specification answers those questions. According to the district court, any questions must be answered by the language of the claims themselves, and a failure to do so renders the claims indefinite as a matter of law.

In a 2-1 decision, the Federal Circuit reversed, holding that the district court’s “unanswered questions” analysis was improper. “Claim language, standing alone” is not the correct legal standard. Patent claims must be read and understood in light of the specification, the prosecution history, and other relevant evidence bearing on how a skilled artisan would understand the scope of the invention. Thus, the district court erred by narrowly focusing only on the claim language and by refusing to consider either the patent specification or the prosecution history.

Having clarified the appropriate legal standard, the majority then reviewed the specification and prosecution history and found the patent claims not indefinite. It identified portions of the patent specification describing the claimed method and noted that it was “not disputed that the specification describes and enables practice of the claimed method.” The majority further noted that the claim language in question was added by the Examiner during prosecution, not the patentee. In light of this fact, the majority deferred to the Examiner’s choice of claim language, quoting an earlier Federal Circuit decision reasoning that “[w]e presume that an examiner would not introduce an indefinite term into a claim when he/she chooses to amend the claim for the very purpose of putting the application in a condition for allowance.” 

Judge Dyk dissented, arguing that the majority gave too much deference to the claim language added by the Examiner. According to Judge Dyk, the claim language included limitations that were not described or defined in the patent specification. And the only evidence about the meaning of the terms came from the defendant’s expert, who testified without contradiction that the additional limitations are “ambiguous,” “unclear,” and inconsistent with the patents’ figures. 

Practice Tips: In any dispute over whether patent claim terms are sufficiently definite, both sides should take care to account for the prosecution history and the patent specification. Moreover, where the challenged claim language was added by the Examiner during prosecution, the accused infringer should give detailed reasons why the court should not defer to the Examiner’s choice of claim language.

Nature Simulation Sys., Inc. v. Autodesk, Inc., 2020-2257 (Fed. Cir. Jan. 27, 2022).

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.